Details

Autor(en) / Beteiligte

• Vermeulen, Isabeau
• Rodriguez-Alvarez, Natalia
• François, Liesbeth
• Viot, Delphine
• Poosti, Fariba
• Aronica, Eleonora
• Dedeurwaerdere, Stefanie
• Barton, Patrick
• Cillero-Pastor, Berta
• Heeren, Ron M.A.

Titel

Spatial omics reveals molecular changes in focal cortical dysplasia type II

Ist Teil von

• Neurobiology of disease, 2024-06, Vol.195, p.106491-106491, Article 106491

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Focal cortical dysplasia (FCD) represents a group of diverse localized cortical lesions that are highly epileptogenic and occur due to abnormal brain development caused by genetic mutations, involving the mammalian target of rapamycin (mTOR). These somatic mutations lead to mosaicism in the affected brain, posing challenges to unravel the direct and indirect functional consequences of these mutations. To comprehensively characterize the impact of mTOR mutations on the brain, we employed here a multimodal approach in a preclinical mouse model of FCD type II (Rheb), focusing on spatial omics techniques to define the proteomic and lipidomic changes. Mass Spectrometry Imaging (MSI) combined with fluorescence imaging and label free proteomics, revealed insight into the brain's lipidome and proteome within the FCD type II affected region in the mouse model. MSI visualized disrupted neuronal migration and differential lipid distribution including a reduction in sulfatides in the FCD type II-affected region, which play a role in brain myelination. MSI-guided laser capture microdissection (LMD) was conducted on FCD type II and control regions, followed by label free proteomics, revealing changes in myelination pathways by oligodendrocytes. Surgical resections of FCD type IIb and postmortem human cortex were analyzed by bulk transcriptomics to unravel the interplay between genetic mutations and molecular changes in FCD type II. Our comparative analysis of protein pathways and enriched Gene Ontology pathways related to myelination in the FCD type II-affected mouse model and human FCD type IIb transcriptomics highlights the animal model's translational value. This dual approach, including mouse model proteomics and human transcriptomics strengthens our understanding of the functional consequences arising from somatic mutations in FCD type II, as well as the identification of pathways that may be used as therapeutic strategies in the future. •Multi-omics reveals FCD type II functional consequences with spatial precision.•mTOR mutations in FCD type II disrupt myelin-related proteins and lipids.•MSI reveals neuronal migration and reduced sulfatides.•Dual approach aligns mouse proteomics with human transcriptomics in FCD type II.